Skip to main
AGL
AGL logo

Agilon Health (AGL) Stock Forecast & Price Target

Agilon Health (AGL) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 18%
Buy 32%
Hold 41%
Sell 9%
Strong Sell 0%

Bulls say

Agilon Health Inc. demonstrated impressive financial performance in the fourth quarter, with total revenue increasing by 44.2% year-over-year, slightly exceeding expectations. The company's membership in Medicare Advantage (MA) grew by 36% year-over-year, reaching 527,000 members, bolstered by steady growth in existing geographies. Additionally, improvements in medical cost tracking and lower-than-anticipated operating expenses suggest a positive trajectory for managing operating efficiency and costs, enhancing the overall outlook for the company's financial health.

Bears say

Agilon Health has faced significant visibility issues concerning utilization forecasting, leading to a negative surprise in financial results for the latter half of 2023, particularly with a reported adjusted EBITDA of $(84.0) million, which was below prior estimates due to lower medical margins. The company's guidance for ACO REACH patients indicates a substantial quarter-over-quarter decline, which raises concerns about future earnings potential, with expected contributions to EBITDA in 2025 aligning closely with previous years despite potential headwinds from exiting an unprofitable partnership. Additionally, Agilon's trading metrics reflect a concerning valuation at 0.2 times projected 2025 revenue, significantly lower than its peers, indicating investor apprehension regarding its financial stability and growth trajectory.

Agilon Health (AGL) has been analyzed by 22 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 32% recommend Buy, 41% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agilon Health (AGL) Forecast

Analysts have given Agilon Health (AGL) a Buy based on their latest research and market trends.

According to 22 analysts, Agilon Health (AGL) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agilon Health (AGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.